Cargando…

Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer

PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) have a negative impact on patients' quality of life and frequently pointed to as a major factor for treatment abandonment. Serotonin (5-HT(3)) receptor antagonist is considered as key treatment for CINV. Ramosetron and palonosetron are re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jin Soo, Kim, Ji Yeon, Lee, Sang-Jeon, Park, Dong Kook, Namgung, Hwan, Kim, Chang Nam, Choi, Won Jun, Baek, Moo Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Surgical Society 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091445/
https://www.ncbi.nlm.nih.gov/pubmed/25025021
http://dx.doi.org/10.4174/astr.2014.87.1.9
_version_ 1782480766691704832
author Kim, Jin Soo
Kim, Ji Yeon
Lee, Sang-Jeon
Park, Dong Kook
Namgung, Hwan
Kim, Chang Nam
Choi, Won Jun
Baek, Moo Jun
author_facet Kim, Jin Soo
Kim, Ji Yeon
Lee, Sang-Jeon
Park, Dong Kook
Namgung, Hwan
Kim, Chang Nam
Choi, Won Jun
Baek, Moo Jun
author_sort Kim, Jin Soo
collection PubMed
description PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) have a negative impact on patients' quality of life and frequently pointed to as a major factor for treatment abandonment. Serotonin (5-HT(3)) receptor antagonist is considered as key treatment for CINV. Ramosetron and palonosetron are recently developed 5-HT(3) receptor antagonists and known as more superior than other first-generation 5-HT(3) receptor antagonists. The purpose of this study was to compare the efficacy of ramosetron and palonosetron and determine which drug is more effective for prevention of CINV. METHODS: Colorectal cancer patients treated with chemotherapy were enrolled consecutively. Patients were assigned to receive intravenous injection of ramosetron 0.3 mg or palonosetron 0.25 mg at 30 minutes before initiation of moderately emetogenic chemotherapy. Ramosetron group added oral administration of 0.1 mg ramosetron on the second and third days of chemotherapy. Efficacy parameter consisted of nausea and vomiting. RESULTS: Ninety-one patients received ramosetron and 89 patients received palonosetron. Presentation of vomiting and nausea symptoms was not significantly different between the two groups during acute (0-24 hours) and delayed period (after 24 hours). CONCLUSION: The incidence of CINV between the ramosetron and the palonosetron group has not shown any difference during acute, delayed, and overall period.
format Online
Article
Text
id pubmed-4091445
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Korean Surgical Society
record_format MEDLINE/PubMed
spelling pubmed-40914452014-07-14 Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer Kim, Jin Soo Kim, Ji Yeon Lee, Sang-Jeon Park, Dong Kook Namgung, Hwan Kim, Chang Nam Choi, Won Jun Baek, Moo Jun Ann Surg Treat Res Original Article PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) have a negative impact on patients' quality of life and frequently pointed to as a major factor for treatment abandonment. Serotonin (5-HT(3)) receptor antagonist is considered as key treatment for CINV. Ramosetron and palonosetron are recently developed 5-HT(3) receptor antagonists and known as more superior than other first-generation 5-HT(3) receptor antagonists. The purpose of this study was to compare the efficacy of ramosetron and palonosetron and determine which drug is more effective for prevention of CINV. METHODS: Colorectal cancer patients treated with chemotherapy were enrolled consecutively. Patients were assigned to receive intravenous injection of ramosetron 0.3 mg or palonosetron 0.25 mg at 30 minutes before initiation of moderately emetogenic chemotherapy. Ramosetron group added oral administration of 0.1 mg ramosetron on the second and third days of chemotherapy. Efficacy parameter consisted of nausea and vomiting. RESULTS: Ninety-one patients received ramosetron and 89 patients received palonosetron. Presentation of vomiting and nausea symptoms was not significantly different between the two groups during acute (0-24 hours) and delayed period (after 24 hours). CONCLUSION: The incidence of CINV between the ramosetron and the palonosetron group has not shown any difference during acute, delayed, and overall period. The Korean Surgical Society 2014-07 2014-06-24 /pmc/articles/PMC4091445/ /pubmed/25025021 http://dx.doi.org/10.4174/astr.2014.87.1.9 Text en Copyright © 2014, the Korean Surgical Society http://creativecommons.org/licenses/by-nc/3.0/ Annals of Surgical Treatment and Research is an Open Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Jin Soo
Kim, Ji Yeon
Lee, Sang-Jeon
Park, Dong Kook
Namgung, Hwan
Kim, Chang Nam
Choi, Won Jun
Baek, Moo Jun
Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer
title Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer
title_full Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer
title_fullStr Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer
title_full_unstemmed Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer
title_short Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer
title_sort multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091445/
https://www.ncbi.nlm.nih.gov/pubmed/25025021
http://dx.doi.org/10.4174/astr.2014.87.1.9
work_keys_str_mv AT kimjinsoo multicenternonrandomizedtrialoframosetronversuspalonosetronincontrollingchemotherapyinducednauseaandvomitingforcolorectalcancer
AT kimjiyeon multicenternonrandomizedtrialoframosetronversuspalonosetronincontrollingchemotherapyinducednauseaandvomitingforcolorectalcancer
AT leesangjeon multicenternonrandomizedtrialoframosetronversuspalonosetronincontrollingchemotherapyinducednauseaandvomitingforcolorectalcancer
AT parkdongkook multicenternonrandomizedtrialoframosetronversuspalonosetronincontrollingchemotherapyinducednauseaandvomitingforcolorectalcancer
AT namgunghwan multicenternonrandomizedtrialoframosetronversuspalonosetronincontrollingchemotherapyinducednauseaandvomitingforcolorectalcancer
AT kimchangnam multicenternonrandomizedtrialoframosetronversuspalonosetronincontrollingchemotherapyinducednauseaandvomitingforcolorectalcancer
AT choiwonjun multicenternonrandomizedtrialoframosetronversuspalonosetronincontrollingchemotherapyinducednauseaandvomitingforcolorectalcancer
AT baekmoojun multicenternonrandomizedtrialoframosetronversuspalonosetronincontrollingchemotherapyinducednauseaandvomitingforcolorectalcancer